Combination of cisplatin and radiation in cell culture: Effect of duration of exposure to drug and timing of irradiation

International Journal of Cancer

Volumn 75, Issue 4, 1998, Pages 635-642

  Gorodetsky, Raphael ^a   Levy Agababa, Floris ^a   Mou, Xiaode ^a   Vexler, Akiva M ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; METHYLENE BLUE;

ANIMAL CELL; ARTICLE; BREAST ADENOCARCINOMA; CANCER CHEMOTHERAPY; CELL CYCLE S PHASE; CELL DENSITY; CELL SURVIVAL; CLINICAL PROTOCOL; COLORIMETRY; CONTROLLED STUDY; DRUG EXPOSURE; HUMAN; HUMAN CELL; IONIZING RADIATION; MOUSE; NONHUMAN; OVARY CARCINOMA; PRIORITY JOURNAL; RADIATION EXPOSURE; TUMOR CELL LINE;

ADENOCARCINOMA; ANIMALS; CARCINOMA; CELL CYCLE; CELL SURVIVAL; CISPLATIN; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; OVARIAN NEOPLASMS; RADIATION-SENSITIZING AGENTS; TIME FACTORS; TUMOR CELLS, CULTURED;

EID: 0032498550     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0215(19980209)75:4<635::AID-IJC23>3.0.CO;2-6     Document Type: Article

References (40)

1. BASHAM, C. MILLS, J. and DOUPLE, E.B., The independent action of radiation and cisplatin on the survival or recovery of human normal or tumor cells in-vitro or in-vivo. Int. J. Radiat. Biol., 55, 807-820 (1989).
2. BELLAMY, A.S. and HILL, B.T., Interactions between clinically effective antitumor drugs and radiation in experimental systems. Biochem. biophys. Acta, 738, 125-166 (1984).
3. BRITTEN, R.A. and WARENIUS, H.M., De novo cisplatinum resistance does not influence cellular radiosensitivity. Europ. J. Cancer, 29A, 1315-1320 (1993).
4. BRITTEN, R.A., WARENIUS, H.M., MASTERS, J.R. and PEACOCK, J.H., The differential induction of collateral resistance to 62.5 MeV (p → Be + ) neutrons and 4 MeV photons by exposure to civ-platinum. Int. J. Radiat. Oncol. Biol. Phys., 26, 837-843 (1993).
5. CARDE, P. and LAVAL, F., Effect of cis-dichlorodiammineplatinum (II) and X-rays on mammalian cell survival. Int. J. Radiat. Oncol. Biol. Phys., 7, 929-933 (1981).
6. CHOU, T.C11 TALALAY, P., Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv. Enzyme Regul., 22, 27-55 (1984).
7. DE POOTER, C.M., SCALLIET, P.G., ELST, H.J., HUYBRECHTS, J.J., GHEENS, E.E.O., VAN OOSTEROM, A.T., FICHTINGER-SCHEPMAN, A.M.J. and DE BRUIJN, E.A., Resistance pattern between cis-diamminedichloroplatinum(II) and ionizing radiation. Cancer Res., 51, 4523-4527 (1991).
8. DEWIT, L., Combined treatment of radiation and cis-diamminedichloroplatinum (II): a review of experimental and clinical data. Int. J. Radiat. Oncol. Biol. Phys., 13, 403-426 (1987).
9. DOUPLE, E.B. and RICHMOND, R.C., A review of interactions between platinum coordination complexes and ionizing radiation: implications for cancer therapy. In: S.T. Cooke and S.K. Carter (eds.), Cisplatin current status and new developments, pp. 125-147, Academic Press. New York (1980).
10. ENSLEY, J.F., JACOBS, J.R., WEAVER, A., KINZIE, J., CRISSMAN, J., KISH, J.A., CUMMINGS, G. and AL-SARRAF, M., Correlation between response to cisplatinum-combination chemotherapy and subsequent radiotherapy in previously untreated patients with advanced squamous cell cancers of the head and neck. Cancer, 54, 811-814 (1984).
11. GORODETSKY, R., MOU, X., PFEFFER, M.R., PERETZ, T. LEVY-AGABABA, F. and VEXLER, A.M., Sub-additive effect of the combination of radiation and cisplatin in cultured murine and human cell lines. Isr. J. med., Sci., 31, 175-180 (1995).
12. GORODOETSKY, R., MOU, X., VEXLER, A.M., KAUFFMAN, B., CATANE, R. and LOEWENTHAL, E., Non-invasive follow-up of platinum pharmacokinetics in the skin of patients on cisplatin chemotherapy. Cancer, 72, 446-454 (1993).
13. HAO, X.Y., BERGH, J., BRODIN, O., HELLMAN, U. and MANNERVIK, B., Acquired resistance to cisplatin and doxorubicin in a small cell lung cancer cell line is correlated to elevated expression of glutathione-linked detoxification enzymes. Carcinogenesis, 15, 1167-1173 (1994).
14. HERMAN, T.S. and TEICHER, B.A., Sequencing of trimodality therapy [cis-diamminedichloroplatinum (II)/hyperthermia/radiation] as determined by tumor growth delay and tumor cell survival in the FSallC fibrosarcoma. Cancer Res., 48, 2693-2697 (1988).
15. HERMAN, T.S., TEICHER, B.A., PFEFFER, M.R., KHANDEKAR, V., CHAPNICK, R.M., KALICK, G.S. and RABOW, A., Effect of acidic pH on radiosensitization of FSallC cells in vitro by rnisonidazole, etamidazole, or cisdiamminedichloroplatinum (II). Radiat. Res., 124, 28-33 (1990).
16. HILL, B.T., Interactions between antitumor agents and radiation and the expression of resistance. Cancer Treat. Rev., 18, 149-190 (1991).
17. HOROWITZ, A.T., TREVES, A.J., Voss, R., OKON, E., FUKS, Z., DAVIDSON, L. and BIRAN, S., A new human carcinoma cell line: establishment and analysis of tumor associated markers. Oncology, 42, 332-337 (1985).
18. KALLMAN, R.F., The importance of schedule and drug dose intensity in combination modalities. Int. J. Radiat. Oncol. Biol. Phys., 28, 761-771 (1994).
19. KORBELK, M. and SKOV, K.A., Inactivation of hypoxic cells by cisplatin and radiation at clinically relevant doses. Radiat. Res., 119, 145-156 (1989).
20. LAGRANGE, J.L., FISHEL, J.L., GALLIANI, S., FORMENTO, P., GUILLOT, T., BARDON, M. and MILANO, G., Importance of the irradiation timing within a chemotherapy sequence including cisplatin and 5FU folinic acid. Experimental results. Europ. J. Cancer, 29, 1531-1535 (1993).
21. r 170,000 glycoprotein (gp170) binding sites. Cancer Res., 54, 441-447 (1994).
22. MATTERN, J., EFFERTH, T. and VOLM, M., Overexpression of P-glycoproteins in human lung carcinoma xenografts after fractionated irradiation in vivo. Radiat. Res., 127, 335-338 (1991).
23. MEIJER, C., MULDER, N.H., HOSPERS, G.A., UGES, D.R. and DE VRIES, E.G., The role of glutathione in resistance to cisplatin in a human small cell lung cancer cell line. Brit. J. Cancer, 62, 72-77 (1990).
24. NAKAMOTO, S., MITSUHASHI, N., TAKAHASHI T., SAKURAI, H. and NIIBE, H., An interaction of cisplatin and radiation in two yolk sac tumour cell lines with different radiosensitivities in vitro. Int. J. Radiat. Biol., 70, 747-753 (1996).
25. NGUYEN, H.N., SKVIN, B.U., AVERETTE, H.E., GOTTLIEB, C., PERRAS, J., DANATO, K. and PENALVER, M., Radiosensitization of uterine cancer cell lines by cytotoxic agents. Gynecol. Oncol., 48, 16-22 (1993).
26. NIAS, A.H.W., Radiation and platinum drug interaction. Int. J. Radiat. Biol., 48, 297-314 (1985).
27. OSHITA, F., FUJIWARA, Y. and SAIJO, N., Radiation sensitivities in various anticancer-drug-resistant human lung cancer cell lines and mechanism of radiation cross-resistance in a cisplatin-resistant cell line. J. Cancer Res. clin. Oncol., 19, 28-34 (1992).
28. PFEFFER, M.R., TEICHER, B.A., HOLDEN, S.A., AL-ACHI, A. and HERMAN, T.S., The interaction of cisplatin plus etoposide with radiation ± hyperthermia. Im. J. Radiat. Oncol. Biol Phys., 19, 1439-1447 (1990).
29. ROCKWELL, S., Cytotoxic and radiosensitizing effects of hypoxic cell sensitizers on EMT6 mouse mammary tumor cells in vivo and in vitro. Brit. J. Cancer, 37, 212-215 (1978).
30. SCHILSKY, R.L., Biochemical pharmacology of chemotherapeutic drugs used as radiation enhancers. Semin. Oncol., 19(Suppl. II). 2-7 (1992).
31. SCHWARTZ, J.L., ROTMENSCH, J., BECKETT, M.A., JAFFE, D.R., TOOHILL, M., GIOVANAZZI, S.M., MCINTOSH, J. and WEICHSELBAUM, R.R., X-ray and cis-diammine-dichloroplatinum (II) cross-resistance in human tumor cell lines. Cancer Res., 48, 5133-5135 (1988).
32. STEEL, G.G., Combination of radiotherapy and chemotherapy. In: G.G. Steel (ed.), Basic clinical radiobiology, pp. 151-162. E. Arnold, London (1993).
33. TWENTYMAN, P.R., WRIGHT, K.A. and RHODES, T., Radiation response of human lung cancer cell lines with acquired and inherent resistance to cisplatin. Int. J. Radiat. Oncol. Biol. Phys., 20, 217-220 (1991).
34. VAN RONGEN, E., KUIJPERS, W.C. and BATEN-WITTWER, A., Time- and sequence-dependent responses to cisplatin and radiation in the rat kidney. Int. J. Radiat. Biol., 59, 537-549 (1991).
35. VEXLER, A.M., MOU, X., GABIZON, A. and GORODETSKY, R., Reduction of the systemic toxicity of cisplatin by intra-arterial hepatic route administration for liver malignancies. Int. J. Cancer, 60, 611-615 (1995).
36. VOKES, E.E., Interactions of chemotherapy and radiation. Semin. Oncol., 20, 70-79 (1993).
37. VON DER MAASE, H., Experimental studies on interactions of radiation and cancer chemotherapeutics in normal tissues and a solid tumor. Radiother. Oncol., 7, 47-68 (1986).
38. WALLNER, K. and LI, G.C., Effect of cisplatin resistance on cellular radiation response. Int. J. Radiat. Oncol. Biol. Phys., 13, 587-591 (1987).
39. YAN, R.D. and DURAND, R.E., The response of hypoxic cells in SCCVII murine tumors to treatment with cisplatin and X-rays. Int. J. Radiat. Oncol. Biol. Phys., 20, 271-274 (1991).
40. ZWELLING, L.A. and KOHN, K.W., Platinum complexes. In: B. Chabner (ed.), Pharmacologic principles of cancer treatment, pp. 322-337. W.B. Saunders, Philadelphia (1982).